Alvotech (ALVO)
Alvotech’s Financial Calendar for 2026
Alvotech (ALVO)
Fjárhagsdagatal Alvotech fyrir árið 2026
Alvotech (ALVO)
Alvotechs Finansiella Kalendar för 2026
Incyte Corporation (INCY)
Incyte Japan gibt die Zulassung von Minjuvi® (Tafasitamab) in Kombination mit Rituximab und Lenalidomid zur Behandlung von rezidiviertem oder refraktärem follikulärem Lymphom bekannt
Ginkgo Bioworks Holdings Inc. (DNA)
Ginkgo Bioworks - Ginkgo Bioworks Partners with Carnegie-Mellon University to Develop Innovative New Cancer Screening Approach
Ginkgo Bioworks Holdings Inc. (DNA)
Ginkgo Bioworks Partners with Carnegie-Mellon University to Develop Innovative New Cancer Screening Approach
Vivos Inc. (RDGL)
Vivos Inc Summarizes Progress in its Animal Therapy Division
Integer Holdings Corp (ITGR)
Deadline Alert: Integer Holdings Corporation (ITGR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Biogen Inc (BIIB)
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
Incyte Corporation (INCY)
Incyte Japan annonce l’autorisation de Minjuvi® (tafasitamab) en association avec le rituximab et le lénalidomide pour le traitement du lymphome folliculaire récidivant ou réfractaire